Physician profile
Nan Wang
NPI 1104807759
$4,140.80
in general payments reported to CMS, 2019-2025
21 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $29.76 · 2021: $192 · 2022: $556 · 2023: $292 · 2024: $1,860 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Travel and Lodging: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.03 |
| Travel and Lodging | $645.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,391.63 | 2022-2025 | Stellaris Elite, Envista Aspire Iol, Teneo |
| Tarsus Pharmaceuticals, INC. | $446.11 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $420.71 | 2019-2025 | Clareon, Rocklatan, Argos |
| Glaukos Corporation | $360.47 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Dompe US, INC. | $289.67 | 2019-2025 | Oxervate |
| Abbvie INC. | $274.90 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.63 | 2019-2021 | |
| Lumenis Be INC | $159.83 | 2025 | M22 |
| Oyster Point Pharma, INC. | $110.76 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $88.38 | 2019-2023 | |
| Tearlab Corp | $67.57 | 2022-2023 | Tearlab Osmolarity System |
| Genentech USA, INC. | $58.71 | 2025 | Susvimo, Vabysmo |
| Carl Zeiss Meditec USA, INC. | $56.37 | 2022 | |
| Horizon Therapeutics Plc | $51.06 | 2023 | Tepezza |
| Thea Pharma INC. | $50.73 | 2022-2025 | Iyuzeh |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $45.61 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $25.44 | 2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $23.68 | 2021 | |
| Biotissue Holdings INC. | $23.54 | 2022 | |
| Amgen INC. | $20.50 | 2025 | Tepezza |
| Optos, INC. | $10.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.